Skip to main content
EJNMMI Research
Fig. 5 | EJNMMI Research

Fig. 5

From: Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy

Fig. 5

A male patient with hepatic neuroendocrine tumor metastases, with the largest lesion measuring 60 mm at screening (A), was treated with whole-liver [166Ho]-radioembolization (B). After 3 months partial response was observed, with the largest lesion measuring 41 mm (C). A clear peak in NLR and TLR can be observed at 3 weeks follow-up (D). FU follow-up

Back to article page